The p53 family: Same response, different signals?

Molecular Medicine Today

Volumn 5, Issue 9, 1999, Pages 387-392

  Chen, Xinbin ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER INHIBITION; CELL CYCLE; GENE CONTROL; GENETIC ORGANIZATION; GENOME IMPRINTING; HUMAN; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FAMILY; REVIEW; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; MEMBRANE PROTEINS; MULTIGENE FAMILY; NUCLEAR PROTEINS; PHOSPHOPROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0032793756     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01545-2     Document Type: Review

References (67)

1. Kaghad M.et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819.
2. Yang A.et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 2:1998;305-316.
3. Trink B.et al. A new human p53 homologue. Nat. Med. 4:1998;747-748.
4. Osada M.et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:1998;839-843.
5. Augustin M., Bamberger C., Paul D., Schmale H. Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm. Genome. 9:1998;899-902.
6. Senoo M.et al. A second p53-related protein, p73L, with high homology to p73. Biochem. Biophys. Res. Commun. 248:1998;603-607.
7. Lee, L.A. et al. Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family, J. Invest. Dermatol. (in press).
8. Bian J., Sun Y. p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family? Proc. Natl. Acad. Sci. U. S. A. 94:1997;14753-14758.
9. Zeng X., Levine A.J., Lu H. Non-p53 p53RE binding protein, a human transcription factor functionally analogous to p53. Proc. Natl. Acad. Sci. U. S. A. 95:1998;6681-6686.
10. Flaman J.M.et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene. 12:1996;813-818.
11. Rehberger P.A.et al. Differential expression of the regularly spliced wild-type p53 and its COOH-terminal alternatively spliced form during epidermal differentiation. Cell Growth Differ. 8:1997;851-860.
12. Almog N.et al. The murine C′-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Mol. Cell. Biol. 17:1997;713-722.
13. De Laurenzi V.et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J. Exp. Med. 188:1998;1763-1768.
14. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
15. Zhu J., Zhou W., Jiang J., Chen X. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J. Biol. Chem. 273:1998;13030-13036.
16. Candau R.et al. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene. 15:1997;807-816.
17. Walker K.K., Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. U. S. A. 93:1996;15335-15340.
18. Evans S.C., Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol. Med. Today. 3:1997;390-395.
19. Lin J., Chen J., Elenbaas B., Levine A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1994;1235-1246.
20. Clurman B., Groudine M. Tumour-suppressor genes. Killer in search of a motive? Nature. 389:1997;122-123.
21. Nomoto S.et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 58:1998;1380-1383.
22. Takahashi H.et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 58:1998;2076-2077.
23. Kovalev S.et al. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ. 9:1998;897-903.
24. Tsao H., Zhang X., Majewski P., Haluska F.G. Mutational and expression analysis of the p73 gene in melanoma cell lines. Cancer Res. 59:1999;172-174.
25. Mai M.et al. Activation of p73 silent allele in lung cancer. Cancer Res. 58:1998;2347-2349.
26. Mai M.et al. Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene. 17:1998;1739-1741.
27. Ichimiya S.et al. p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene. 18:1999;1061-1066.
28. Han S.et al. Infrequent somatic mutations of the p73 gene in various human cancers. Eur. J. Surg. Oncol. 25:1999;194-198.
29. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991.
30. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:1998;725-734.
31. Quelle D.E., Cheng M., Ashmun R.A., Sherr C.J. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc. Natl. Acad. Sci. U. S. A. 94:1997;669-673.
32. Di Como C.J., Gaiddon C., Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19:1999;1438-1449.
33. Mills A.A.et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 398:1999;708-713.
34. Yang A.et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 398:1999;714-718.
35. Lane D.P. p53, guardian of the genome. Nature. 358:1992;15-16.
36. Giaccia A.J., Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:1998;2973-2983.
37. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
38. Agarwal M.L.et al. The p53 network. J. Biol. Chem. 273:1998;1-4.
39. Canman C.E.et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
40. Marin M.C.et al. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell. Biol. 18:1998;6316-6324.
41. Higashino F., Pipas J.M., Shenk T. Adenovirus E4orf6 oncoprotein modulates the function of the p53-related protein, p73. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15683-15687.
42. Roth J.et al. Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins. J. Virol. 72:1998;8510-8516.
43. Steegenga W.T.et al. Distinct regulation of p53 and p73 activity by adenovirus EIA, E1B, and e4orf6 proteins. Mol. Cell. Biol. 19:1999;3885-3894.
44. Jost C.A., Marin M.C., Kaelin W.G. Jr. p73 is a human p53-related protein that can induce apoptosis. Nature. 389:1997;191-194.
45. Zhu J., Jiang J., Zhou W., Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58:1998;5061-5065.
46. el-Deiry W.S.et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
47. Xiong Y.et al. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
48. Harper J.W.et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
49. Wang X.W.et al. GADD45 induction of a G2/M cell cycle checkpoint. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3706-3711.
50. Rouault J.P.et al. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat. Genet. 14:1996;482-486.
51. Hermeking H.et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell. 1:1997;3-11.
52. Peng C.Y.et al. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science. 277:1997;1501-1505.
53. Miyashita T.et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
54. Polyak K.et al. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
55. Yin Y.et al. Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature. 391:1998;707-710.
56. Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
57. Grossman S.R.et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell. 2:1998;405-415.
58. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
59. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
60. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
61. Oliner J.D.et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
62. Zeng X.et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19:1999;3257-3266.
63. Dobbelstein M., Wienzek S., Konig C., Roth J. Inactivation of the p53 homologue p73 by the mdm2-oncoprotein. Oncogene. 18:1999;2101-2106.
64. Donehower L.A.et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
65. Gong J.et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 399:1999;806-809.
66. Agami R.et al. Interaction of c-Abl and p73a and their collaboration to induce apoptosis. Nature. 399:1999;809-813.
67. Yuan Z-M.et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 399:1999;814-817.